SCHEMBL2146546

SCHEMBL2146546

Cc1noc(C)c1-c1c(C=NO)c2ccc(F)cc2n1-c1ccc(O)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.37
NSD3 Q9BZ95 1/20 0.37
BRD4 O60885 7/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.36
USP2 O75604 2/20 0.35
LMNA P02545 2/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2C19 P33261 2/20 0.35
ALDH1A1 P00352 2/20 0.35
ALOX15 P16050 2/20 0.35
MEN1 O00255 1/20 0.35
APEX1 P27695 1/20 0.35
KMT2A Q03164 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ERN1 O75460 3/20 0.34
MAPK14 Q16539 1/20 0.33
DGAT2 Q96PD7 1/20 0.33
GRIA1 P42261 1/20 0.32
CACNG8 Q8WXS5 1/20 0.32
CACNG2 Q9Y698 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2146543 1.00 PIK3CD (0.37) PIK3CDNSD3BRD4PTGDR2USP2
SCHEMBL2146838 0.92 PTGDR2 (0.39) PIK3CDNSD3BRD4PTGDR2USP2
SCHEMBL2146833 0.92 PTGDR2 (0.39) PIK3CDNSD3BRD4PTGDR2USP2
SCHEMBL2146304 0.89 ERN1 (0.36) PIK3CDBRD4PTGDR2USP2LMNA
SCHEMBL2146302 0.89 ERN1 (0.36) PIK3CDBRD4PTGDR2USP2LMNA
SCHEMBL2146755 0.88 BRD4 (0.36) BRD4LMNAKMT2AERN1SMN1; SMN2
SCHEMBL2146748 0.88 BRD4 (0.36) BRD4LMNAKMT2AERN1SMN1; SMN2
SCHEMBL2146513 0.88 MLYCD (0.34) PIK3CDBRD4LMNAERN1
SCHEMBL2146509 0.88 MLYCD (0.34) PIK3CDBRD4LMNAERN1
SCHEMBL2146930 0.86 ESR2 (0.39) BRD4USP2LMNACYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102216268-A Novel estrogen receptor ligands KAROBIO AB 2011-10-12 CN claimed
US-20110201555-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-08-18 US claimed
EP-2346824-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-07-27 EP claimed
WO-2010031852-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2010-03-25 WO claimed
US-20110201555-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-08-18 US disclosed
EP-2346824-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-07-27 EP disclosed
WO-2010031852-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2010-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201555-A1 NOVEL ESTROGEN RECEPTOR LIGANDS ESR1, ESRRA, GPER1 PIK3CD 4139/4885NSD3 1570/4885BRD4 891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.